Hillstream BioPharma, Inc. (HILS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Bridgewater, NJ, United States. The current CEO is Randy D. Milby MBA.
HILS has IPO date of 2022-01-12, 1 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $4.17M.
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
